Barbara Weber Sells 9,778 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber sold 9,778 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total transaction of $29,236.22. Following the sale, the chief executive officer now directly owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. The trade was a 0.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Tango Therapeutics Price Performance

Shares of NASDAQ:TNGX opened at $3.03 on Friday. Tango Therapeutics, Inc. has a 12 month low of $2.59 and a 12 month high of $12.80. The firm has a market capitalization of $325.48 million, a price-to-earnings ratio of -2.57 and a beta of 0.80. The business’s 50 day simple moving average is $3.12 and its 200-day simple moving average is $6.10.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on TNGX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. Guggenheim cut their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Tango Therapeutics in a research report on Friday, November 8th. Finally, B. Riley cut their price target on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tango Therapeutics has an average rating of “Buy” and an average price target of $13.14.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TNGX. State Street Corp increased its holdings in Tango Therapeutics by 26.8% during the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after acquiring an additional 489,949 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Tango Therapeutics by 11.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock worth $10,538,000 after purchasing an additional 142,710 shares in the last quarter. Barclays PLC raised its position in shares of Tango Therapeutics by 78.3% during the 3rd quarter. Barclays PLC now owns 126,281 shares of the company’s stock worth $972,000 after purchasing an additional 55,470 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Tango Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after buying an additional 100,257 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in Tango Therapeutics during the 3rd quarter valued at $247,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.